65,437 trials
Hyperlipidemia · Coronary Artery Disease
Primary: Number of Subjects Who Meet Low-density Lipoprotein (LDL) at Goal (<55) — 17; 3 Participants — p=<0.001
Opioid-use Disorder · Stress Related Disorder · Anxiety
Primary: Number of Biochemically-confirmed Opioid Abstinent 2-week Time Periods — 13.4; 12.7 percentage of 2-week time periods
Hypertension · Aging · Sedentary Lifestyle
Primary: Change in Gait Speed From Baseline — 0.10; 0.05; 0.10 m/sec
Pulmonary Hypertension
Primary: Number of Patients Undertaking an App-based 6MWT — 24 Participants
Cirrhosis, Liver · Portal Hypertension · Ascites Hepatic
Primary: Change in Mean Arterial Pressure — 0.5; 1 mmHg
Telemedicine · Heart Failure · Defibrillators
Primary: Percentage of Participants With Interventional Procedures Successfully Completed — 10; 20 Participants
AIDS
Primary: Proportion of Patients Free of Therapeutic Failure — 47; 20; 0; 2 Participants
HIV Infection · Hepatitis B
Primary: Percentage of Participants With Primary Seroprotection Response — 93.1; 99.4; 80.6; 100 percentage of participants
Desmoplastic Small Round Cell Tumor
Primary: Progression Free Survival (PFS) — NA; NA Months
Osteoporosis · Aging
Primary: C-telopeptide of Type I Collagen (CTX) Change — 0.09; 0.08 ng/mL
Safety and Tolerability · Healthy Volunteers
Primary: Safety and Tolerability — 7; 8; 12; 3 AEs
Immediate Dental Implant Loading · Denture, Complete
Primary: Radiographic Bone Level (RBL) Change — 0.14 millimeters (mm)
Obesity
Primary: Weight (kg) — -3.61; -3.31; -3.32; -3.60 kg — p=0.52
Covid19
Primary: Time to Sustained Recovery in Days — 9; 10 days
Sickle Cell Disease (SCD)
Primary: Pharmacokinetics (PK): AUCd15 of Crizanlizumab After First Dose - Part A — 10500; 8180; 20600; 14400 hr*ug/mL